Genomic scarring score predicts the response to PARP inhibitors in non-small cell lung cancer

Abstract PARP inhibitors (PARPi) have shown efficacy in tumours harbouring mutations in homologous recombination repair (HRR) genes. Somatic HRR mutations have been described in patients with Non-Small Cell Lung Cancer (NSCLC), but PARP inhibitors (PARPi) are not yet a therapeutic option. Here we as...

Descripció completa

Dades bibliogràfiques

Autors principals:	Katerina Tsilingiri, Anna Chalari, Georgia Christopoulou, Alexandra Voutsina, Pantelis Constantoulakis, Κonstantinos Potaris, Ioannis Vamvakaris, Dora Hatzidaki, Georgina Zachou, Giannis Vatsellas, Vassilis Georgoulias, Athanasios Kotsakis, Apostolos Klinakis
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2024-12-01
Col·lecció:	npj Precision Oncology
Accés en línia:	https://doi.org/10.1038/s41698-024-00777-6
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!